BioStem Technologies Publicly Files Form 10 Registration Statement with the Securities and Exchange Commission

BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced the filing of a Form 10 registration statement (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) to register its shares of common stock pursuant to the Securities Exchange Act of 1934, as amended, and reaffirmed its strategic decision to pursue a listing on the Nasdaq Stock Market (“Nasdaq”). “The filing of our Registration Statement is an important milestone that advances our path toward a Nasdaq uplisting and reflects our significant commitment to operating as an SEC reporting company,” said Jason Matuszewski, Chief Executive Officer and Chairman of BioStem Technologies. “We believe this is the right step for the Company as we continue to strengthen our position in the public markets. Completing the registration process will be a pivotal step toward a Nasdaq uplisting and will enhance our credibility, expand access to capital, improve market visibility and liquidity, and reinforce our ability to attract exceptional talent as we continue to grow. Together, we believe these advantages will better position BioStem to execute our long-term growth strategy and create sustainable value for shareholders.” The Registration Statement has not been declared effective by the SEC. The Registration Statement will become effective following conclusion of the SEC’s review of the Registration Statement. An effective Registration S...